Adefovir_dipivoxil has been approved in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


adefovir_dipivoxil studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
ADF 103814 IV An open label, multicenter phase IV study of adefovir dipivoxil in Korean patients with chronic hepatitis B (CHB)
ADF20001 IV Open label compassionate access programme to provide adefovir dipivoxil to patients with chronic hepatitis B infection.
ADF30001 (Year 1 and Year 2) III A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data)
ADF30001 (Year 1 to Year 3) III A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on interim data out to 3 years)
ADF30001 (Year 1 to Year 4) III A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on data out to 4 years)
ADF30003 III Clinical Evaluation of Adefovir Dipivoxil (GW284873X) in Patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy – A follow-up long term study of ADF30002 (a 16 week open label study).